Prioritizing genomic drug targets in pathogens: Application to Mycobacterium tuberculosis

PLoS Computational Biology

Volumn 2, Issue 6, 2006, Pages 0539-0550

  Hasan, Samiul ^a   Daugelat, Sabine ^a   Rao, P S Srinivasa ^a   Schreiber, Mark ^a  

^a Novartis Institute for Tropical Diseases (NITD)   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

COMPUTER PROGRAMMING; GENOME; SOFTWARE AGENTS; TUBES (COMPONENTS);

ACTINOBACTERIA; CAUSATIVE AGENTS; DRUG TARGETS; GENOMICS; M. TUBERCULOSIS; METABOLOMES; MYCOBACTERIUM TUBERCULOSIS; SMALL MOLECULES; SOFTWARE PROJECT; SPECIFIC PROPERTIES;

METABOLISM;

ACTINOBACTERIA; ALGORITHM; ARTICLE; COMPUTER PROGRAM; DRUG TARGETING; GENE EXPRESSION; GENOMICS; HUMAN; INFORMATION SCIENCE; INTESTINE FLORA; MYCOBACTERIUM TUBERCULOSIS; PATHOGENESIS; SEQUENCE HOMOLOGY; TUBERCULOSIS; ANTIBIOTIC RESISTANCE; BIOLOGY; CHEMISTRY; DRUG DESIGN; DRUG INDUSTRY; METABOLISM; METHODOLOGY; MULTIDRUG RESISTANCE; PHARMACOGENETICS;

ACTINOBACTERIA; MYCOBACTERIUM TUBERCULOSIS;

DRUG;

ALGORITHMS; COMPUTATIONAL BIOLOGY; DRUG DESIGN; DRUG INDUSTRY; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE; MYCOBACTERIUM TUBERCULOSIS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; SOFTWARE; TUBERCULOSIS;

EID: 33745607880     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.0020061     Document Type: Article

References (71)

1. Humer F (2005) Innovation in the Pharmaceutical Industry - Future Prospects. Available: http://www.roche.com/fbh_zvg05_e.pdf. Accessed 12 May 2006.
2. Terstappen GC, Reggiani A (2001) In silico research in drug discovery. Trends Pharmacol Sci 22: 23-26.
3. Freiberg C (2001) Novel computational methods in anti-microbial target identification. Drug Discovery Today 6: S72-S80.
4. Wang S, Sim TB, Kim YS, Chang YT (2004) Tools for target identification and validation. Curr Opin Chem Biol 8: 371-377.
5. Sanseau P (2001) Impact of human genome sequencing for in silico target discovery. Drug Discov Today 6: 316-323.
6. Freiberg C, Wieland B, Spaltmann F, Ehlert K, Brotz H, et al. (2001) Identification of novel essential Escherichia coli genes conserved among pathogenic bacteria. J Mol Microbiol Biotechnol 3: 483-489.
7. Roemer T, Jiang B, Davison J, Ketela T, Veillette K, et al. (2003) Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery. Mol Microbiol 50: 167-181.
8. Sassetti CM, Boyd DH, Rubin EJ (2003) Genes required for mycobacterial growth defined by high density mutagenesis. Mol Microbiol 48: 77-84.
9. Wixon J, Kell D (2000) The Kyoto encyclopedia of genes and genomes - KEGG. Yeast 17: 48-55.
10. Tatusov RL, Koonin EV, Lipman DJ (1997) A genomic perspective on protein families. Science 278: 631-637.
11. Hopkins AL, Groom CR (2002) The druggable genome. Nat Rev Drug Discov 1: 727-730.
12. Robertson JG (2005) Mechanistic basis of enzyme-targeted drugs. Biochemistry 44: 8918.
13. World Health Organization (2005) Global tuberculosis control - Surveillance, planning, financing. Available: http://www.who.int/tb/ publications/global_report/en. Accessed 12 May 2006.
14. Zhang Y (2004) Persistent and dormant tubercle bacilli and latent tuberculosis. Front Biosci 9: 1136-1156.
15. Duncan K (2004) Identification and validation of novel drug targets in tuberculosis. Curr Pharm Des 10: 3185-3194.
16. Zhang Y (2005) The magic bullets and tuberculosis drug targets. Annu Rev Pharmacol Toxicol 45: 529-564.
17. Zhang Y, Amzel LM (2002) Tuberculosis drug targets. Curr Drug Targets 3: 131-154.
18. Zhang Y, Mitchison D (2003) The curious characteristics of pyrazinamide: A review. Int J Tuberc Lung Dis 7: 6-21.
19. Chopra I, Hesse L, O'Neill AJ (2002) Exploiting current understanding of antibiotic action for discovery of new drugs. Symp Ser Soc Appl Microbiol: 4S-15S.
20. Sassetti CM, Boyd DH, Rubin EJ (2001) Comprehensive identification of conditionally essential genes in mycobacteria. Proc Natl Acad Sci U S A 98: 12712-12717.
21. Lamichhane G, Zignol M, Blades NJ, Geiman DE, Dougherty A, et al. (2003) A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: Application to Mycobacterium tuberculosis. Proc Natl Acad Sci U S A 100: 7213-7218.
22. Tsolaki AG, Hirsh AE, DeRiemer K, Enciso JA, Wong MZ, et al. (2004) Functional and evolutionary genomics of Mycobacterium tuberculosis: Insights from genomic deletions in 100 strains. Proc Natl Acad Sci U S A 101: 4865-4870.
23. Mulder NJ, Apweiler R, Attwood TK, Bairoch A, Bateman A, et al. (2005) InterPro, progress and status in 2005. Nucleic Acids Res 33: D201-205.
24. Yeh I, Hanekamp T, Tsoka S, Karp PD, Altman RB (2004) Computational analysis of Plasmodium falciparum metabolism: Organizing genomic information to facilitate drug discovery. Genome Res 14: 917-924.
25. Terwilliger TC, Park MS, Waldo GS, Berendzen J, Hung LW, et al. (2003) The TB structural genomics consortium: A resource for Mycobacterium tuberculosis biology. Tuberculosis (Edinb) 83: 223-249.
26. Alfarano C, Andrade CE, Anthony K, Bahroos N, Bajec M, et al. (2005) The Biomolecular Interaction Network Database and related tools 2005 update. Nucleic Acids Res 33: D418-D424.
27. Schnappinger D, Ehrt S, Voskuil MI, Liu Y, Mangan JA, et al. (2003) Transcriptional Adaptation of Mycobacterium tuberculosis within macrophages: Insights into the phagosomal environment. J Exp Med 198: 693-704.
28. Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrell MI, et al. (2001) Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-crystallin. Proc Natl Acad Sci U S A 98: 7534-7539.
29. Hampshire T, Soneji S, Bacon J, James BW, Hinds J, et al. (2004) Stationary phase gene expression of Mycobacterium tuberculosis following a progressive nutrient depletion: A model for persistent organisms? Tuberculosis (Edinb) 84: 228-238.
30. Betts JC, Lukey PT, Robb LC, McAdam RA, Duncan K (2002) Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling. Mol Microbiol 43: 717-731.
31. Muttucumaru DG, Roberts G, Hinds J, Stabler RA, Parish T (2004) Gene expression profile of Mycobacterium tuberculosis in a non-replicating state. Tuberculosis (Edinb) 84: 239-246.
32. Voskuil MI, Visconti KC, Schoolnik GK (2004) Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy. Tuberculosis (Edinb) 84: 218-227.
33. Boshoff HI, Myers TG, Copp BR, McNeil MR, Wilson MA, et al. (2004) The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: Novel insights into drug mechanisms of action. J Biol Chem 279: 40174-40184.
34. Martz E (2001) Homology modeling for beginners. Available: http://www.umass.edu/molvis/workshop/homolmod.htm. Accessed 12 May 2006.
35. Mitchison DA (2004) The search for new sterilizing anti-tuberculosis drugs. Front Biosci 9: 1059-1072.
36. Glickman MS, Cox JS, Jacobs WR Jr. (2000) A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol Cell 5: 717-727.
37. Sun Z, Zhang Y (1999) Antituberculosis activity of certain antifungal and antihelmintic drugs. Tuber Lung Dis 79: 319-320.
38. Rodriguez GM, Voskuil MI, Gold B, Schoolnik GK, Smith I (2002) ideR, An essential gene in Mycobacterium tuberculosis: Role of IdeR in iron-dependent gene expression, iron metabolism, and oxidative stress response. Infect Immun 70: 3371-3381.
39. Boon C, Dick T (2002) Mycobacterium bovis BCG response regulator essential for hypoxic dormancy. J Bacteriol 184: 6760-6767.
40. Voskuil MI, Schnappinger D, Visconti KC, Harrell MI, Dolganov GM, et al. (2003) Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 198: 705-713.
41. Bateman A, Coin L, Durbin R, Finn RD, Hollich V, et al. (2004) The Pfam protein families database. Nucleic Acids Res 32: D138-D141.
42. Andries K, Verhasselt P, Guillemont J, Gohlmann HW, Neefs JM, et al. (2005) A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307: 223-227.
43. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ (1990) Basic local alignment search tool. J Mol Biol 215: 403-410.
44. Tatusov RL, Fedorova ND, Jackson JD, Jacobs AR, Kiryutin B, et al. (2003) The COG database: An updated version includes eukaryotes. BMC Bioinformatics 4: 41.
45. Draghici S, Khatri P, Eklund AC, Szallasi Z (2006) Reliability and reproducibility issues in DNA microarray measurements. Trends Genet 22: 101-109.
46. McKinney JD, Honer zu Bentrup K, Munoz-Elias EJ, Miczak A, Chen B, et al. (2000) Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 406: 735-738.
47. Dahl JL, Kraus CN, Boshoff HI, Doan B, Foley K, et al. (2003) The role of RelMtb-mediated adaptation to stationary phase in long-term persistence of Mycobacterium tuberculosis in mice. Proc Natl Acad Sci U S A 100: 10026-10031.
48. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z (2003) Mode of action of pyrazinamide: Disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 52: 790-795.
49. Maggi N, Pasqualucci CR, Ballotta R, Sensi P (1966) Rifampicin: A new orally active rifamycin. Chemotherapy 11: 285-292.
50. Takayama K, Kilburn JO (1989) Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis. Antimicrob Agents Chemother 33: 1493-1499.
51. Garvin RT, Biswas DK, Gorini L (1974) The effects of streptomycin or dihydrostreptomycin binding to 16S RNA or to 30S ribosomal subunits. Proc Natl Acad Sci U S A 71: 3814-3818.
52. Winder FG, Collins PB (1970) Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis. J Gen Microbiol 63: 41-48.
53. Banerjee A, Dubnau E, Quemard A, Balasubramanian V, Um KS, et al. (1994) inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263: 227-230.
54. Jacobs MR (1995) Activity of quinolones against mycobacteria. Drugs 49 (Suppl 2):: 67-75.
55. Rando RR (1975) On the mechanism of action of antibiotics which act as irreversible enzyme inhibitors. Biochem Pharmacol 24: 1153-1160.
56. Locher HH, Schlunegger H, Hartman PG, Angehrn P, Then RL (1996) Antibacterial activities of epiroprim, a new dihydrofolate reductase inhibitor, alone and in combination with dapsone. Antimicrob Agents Chemother 40: 1376-1381.
57. Huovinen P, Sundstrom L, Swedberg G, Skold O (1995) Trimethoprim and sulfonamide resistance. Antimicrob Agents Chemother 39: 279-289.
58. Belisle JT, Vissa VD, Sievert T, Takayama K, Brennan PJ, et al. (1997) Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276: 1420-1422.
59. Leys D, Mowat CG, McLean KJ, Richmond A, Chapman SK, et al. (2003) Atomic structure of Mycobacterium tuberculosis CYP121 to 1.06 A reveals novel features of cytochrome P450. J Biol Chem 278: 5141-5147.
60. Cynamon MH, Alvirez-Freites E, Yeo AE (2004) BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis. J Antimicrob Chemother 53: 403-405.
61. Primm TP, Andersen SJ, Mizrahi V, Avarbock D, Rubin H, et al. (2000) The stringent response of Mycobacterium tuberculosis is required for long-term survival. J Bacteriol 182: 4889-4898.
62. Gokulan K, Rupp B, Pavelka MS Jr., Jacobs WR Jr., Sacchettini JC (2003) Crystal structure of Mycobacterium tuberculosis diaminopimelate decarboxylase, an essential enzyme in bacterial lysine biosynthesis. J Biol Chem 278: 18588-18596.
63. Pavelka MS Jr., Jacobs WR Jr. (1999) Comparison of the construction of unmarked deletion mutations in Mycobacterium smegmatis, Mycobacterium bovis bacillus Calmette-Guerin, and Mycobacterium tuberculosis H37Rv by allelic exchange. J Bacteriol 181: 4780-4789.
64. Sambandamurthy VK, Wang X, Chen B, Russell RG, Derrick S, et al. (2002) A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat Med 8: 1171-1174.
65. Parish T, Stoker NG (2000) glnE is an essential gene in Mycobacterium tuberculosis. J Bacteriol 182: 5715-5720.
66. Tullius MV, Harth G, Horwitz MA (2003) Glutamine synthetase GlnA1 is essential for growth of Mycobacterium tuberculosis in human THP-1 macrophages and guinea pigs. Infect Immun 71: 3927-3936.
67. Parish T, Stoker NG (2002) The common aromatic amino acid biosynthesis pathway is essential in Mycobacterium tuberculosis. Microbiology 148: 3069-3077.
68. Pan F, Jackson M, Ma Y, McNeil M (2001) Cell wall core galactofuran synthesis is essential for growth of mycobacteria. J Bacteriol 183: 3991-3998.
69. Schmitt MP, Predich M, Doukhan L, Smith I, Holmes RK (1995) Characterization of an iron-dependent regulatory protein (IdeR) of Mycobacterium tuberculosis as a functional homolog of the diphtheria toxin repressor (DtxR) from Corynebacterium diphtheriae. Infect Immun 63: 4284-4289.
70. Niederweis M (2003) Mycobacterial porins - New channel proteins in unique outer membranes. Mol Microbiol 49: 1167-1177.
71. Sareen D, Newton GL, Fahey RC, Buchmeier NA (2003) Mycothiol is essential for growth of Mycobacterium tuberculosis Erdman. J Bacteriol 185: 6736-6740.